Drug Trial Radar · NCT07599670
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
May 15, 2026
Primary completion
Oct 2030
Study completion Oct 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. The purpose of this study is to test how safe ABBV-1758 is, how well it works, how the body processes it and what effects it has on the body. ABBV-1758 is an investigational drug being developed for the treatment of Alzheimer's disease. This study is conducted in 3 stages. Stage A is a multiple ascending dose study with a 1 in 5 chance (4:1 randomization) that participants are assigned to receive placebo. Stage B is a dose expansion phase, also using 4:1 randomization for ABBV-1758 or placebo. Stage C enrolls Japanese and Chinese participants with the same randomization scheme. Approximately 210 participants will be enrolled at about 55 sites in the United States, China, and Japan. Participants will receive intravenous (IV) or subcutaneous (SC) doses of ABBV-1758 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for additional 12 weeks in the Follow-up Period. Participants will have the option of participating in a 12-month, blinded Extension Period receiving ABBV-1758 or placebo based on amyloid PET results. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The safety of the treatment will be checked by medical assessments, blood tests, and completing questionnaires.
Conditions
- Alzheimer's Disease
Interventions
ABBV-1758Drug
Intravenous (IV) or Subcutaneous (SC)
Placebo for ABBV-1758Drug
Intravenous (IV) or Subcutaneous (SC)
ABBV-1758Drug
Subcutaneous (SC)
Placebo for ABBV-1758Drug
Subcutaneous (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Adverse Events (AEs)Time frame: Up to approximately 40 weeks
- Percentage of Participants with Abnormal Change from Baseline in Clinical Laboratory Test ResultsTime frame: Up to approximately 40 weeks
- Percentage of Participants With Amyloid-Related Imaging Abnormalities (ARIA)Time frame: Up to approximately 40 weeks
- Percentage of Participants with Abnormal Change From Baseline in Vital Sign MeasurementsTime frame: Up to approximately 40 weeks
- Percentage of Participants with Abnormal Change From Baseline in Electrocardiograms (ECGs) ParametersTime frame: Up to approximately 40 weeks
- Percentage of Participants Experiencing Any Suicidal Ideation or Suicidal Behavior As Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to approximately 40 weeks
- Stage A, B, and C: Change from Baseline in Brain Amyloid LoadTime frame: Up to approximately 28 Weeks
- Stage A and C: Maximum Plasma Concentration (Cmax) of ABBV-1758Time frame: Up to approximately 40 weeks
- Stage A and C: Time to Cmax (Tmax) of ABBV-1758Time frame: Up to approximately 40 weeks
- Stage A and C: Trough Concentration measured at the end of a dosing interval at steady state (Ctrough) of ABBV-1758Time frame: Up to approximately 40 weeks
- Stage A and C: Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau) of ABBV-1758Time frame: Up to approximately 40 weeks
- Stage A and C: Average Serum Concentration at Steady-State (Cav,ss) of ABBV-1758Time frame: Up to approximately 40 weeks
- Stage A and C: Accumulation ratio for (AUCtau) of ABBV-1758Time frame: Up to approximately 40 weeks
- Stage A and C: Total Body Clearance (CL) of ABBV-1758Time frame: Up to approximately 40 weeks
- Stage A and C: Apparent Clearance (CL/F) of ABBV-1758Time frame: Up to approximately 40 weeks
- Stage A and C: Volume of Distribution at Steady-State (Vss)Time frame: Up to approximately 40 weeks
- Stage A and C: Apparent Volume of Distribution during the Terminal Phase (Vz)Time frame: Up to approximately 40 weeks
- Stage A and C: Terminal Phase Elimination Rate Constant (β) of ABBV-1758Time frame: Up to approximately 40 weeks
- Stage A and C: Terminal Phase Elimination Half-Life (t1/2) of ABBV-1758Time frame: Up to approximately 40 weeks
- Stage A and C: Effective Half-Life (T1/2,eff)Time frame: Up to approximately 40 weeks
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Irvine Center for Clinical Research /ID# 277752
Irvine, California · Recruiting
Alpine Clinical Research Center - Boulder - 47th Street /ID# 277856
Boulder, Colorado · Recruiting
Key Clinical Research LLC /ID# 277800
Bradenton, Florida · Recruiting
K2 Medical Research - Clermont /ID# 277859
Clermont, Florida · Recruiting
K2 Medical Research - The Villages /ID# 278290
Lady Lake, Florida · Recruiting
Alzheimer'S Research And Treatment Center - Stuart /ID# 278206
Stuart, Florida · Recruiting
Alzheimer's Research And Treatment Center - Wellington /ID# 277749
Wellington, Florida · Recruiting
Conquest Research - Winter Park /ID# 277760
Winter Park, Florida · Recruiting
Adams Clinical /ID# 277754
Watertown, Massachusetts · Recruiting
Neurology Clinic - Cordova /ID# 277790
Cordova, Tennessee · Recruiting
Kerwin Medical Center /ID# 277788
Dallas, Texas · Recruiting
Xuanwu Hospital Capital Medical University /ID# 283310
Beijing, Beijing Municipality, China · Recruiting
The Second Affiliated Hospital of Guangzhou Medical University /ID# 284295
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.